Elanco Animal Health Incorporated ELAN

Set alert

Price alert · ELAN

All alert types
24.75 USD +0.64 +2.68%

As of Nov 3, 12:00 PM ET

Bid
24.74 × 1
Ask
24.75 × 1
24.09 Day range 24.81
19.80 52-week range 26.84
YTD
+9.35%
1 year
+8.29%
Open
24.23
Prev close
24.10
Mkt cap
12.37B
Vol
1.30M
Avg vol
6.17M
EPS
-0.41
P/E
0.00
Div yield
0.00%
More statistics
Low
24.09
High
24.81
Forward P/E
18.93
Beta
1.72
Short ratio
5.57
Inst. own
115.51%
Dividend
0.00
Ex-div date
Earnings
Nov 6, 2026
50-d avg
23.12
200-d avg
23.79
1y target
30.23

6M chart

Chart tools
Interval

Events in this range
  • May 6, 2026Earnings: 0.4; estimate 0.3456; surprise 15.74%
  • Jul 22, 2026Rating: Morgan Stanley · Equal-Weight → Equal-Weight
  • Aug 5, 2026Earnings: 0.34; estimate 0.2692; surprise 26.3%
  • Aug 6, 2026Rating: Keybanc · Overweight → Overweight
  • Aug 6, 2026Rating: UBS · Buy → Buy
  • Oct 16, 2026Rating: Goldman Sachs · — → Buy
  • Oct 20, 2026Downgrade: Jefferies · Buy → Hold
  • Oct 29, 2026Rating: Morgan Stanley · Equal-Weight → Equal-Weight
Signals (46)
NameDateAgo
SMA: BullishNov 2, 20261 day ago
SMA: BullishNov 2, 20261 day ago
SMA: BearishOct 30, 20264 days ago
SMA: BullishOct 29, 20265 days ago
SMA: BearishOct 20, 20262 weeks ago
SMA: BullishOct 15, 20262 weeks ago
MACD: Buy SignalOct 5, 20264 weeks ago
SMA: BearishSep 9, 20261 month ago
MACD: Sell SignalSep 9, 20261 month ago
SMA: BearishSep 3, 20262 months ago
SMA: BullishSep 2, 20262 months ago
SMA: BearishAug 27, 20262 months ago
SMA: BullishAug 25, 20262 months ago
SMA: BullishAug 21, 20262 months ago
MACD: Buy SignalAug 21, 20262 months ago
SMA: BearishAug 20, 20262 months ago
SMA: BullishAug 19, 20262 months ago
SMA: BearishAug 7, 20262 months ago
SMA: BearishAug 6, 20262 months ago
MACD: Sell SignalAug 4, 20263 months ago

Newest 20 of 46.

Key statistics

Market cap
12.03B
Enterprise value
15.22B
Trailing P/E
0.00
Forward P/E
18.93
PEG ratio
4.04
Price / sales
2.40
Price / book
1.83
EPS (TTM)
-0.41
Beta
1.72
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-3.96%
Revenue (TTM)
5.02B
Revenue growth
10.20%
Free cash flow
826.88M
Total cash
530.00M
Total debt
4.23B
Return on equity
-2.98%
Shares outstanding
499.45M
Short % of float
9.89%
50-day average
23.12
200-day average
23.79

Financials — quick view

All financials
ELAN Revenue — quarterly 1.37B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ELAN Net income — quarterly 54.00M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ELAN EPS — quarterly 0.11
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

ELAN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 6, 2026Sep 30, 20260.2028———
Aug 5, 2026Jun 30, 20260.26920.34+0.07+26.30%
May 6, 2026Mar 31, 20260.34560.40+0.05+15.74%
Feb 24, 2026Dec 31, 20250.110.13+0.02+18.18%
Nov 5, 2025Sep 30, 20250.130.19+0.06+46.15%
Aug 7, 2025Jun 30, 20250.200.26+0.06+30.00%

Upgrades / downgrades

ELAN analyst upgrades and downgrades
DateFirmActionFromTo
Oct 29, 2026Morgan StanleymainEqual-WeightEqual-Weight
Oct 20, 2026JefferiesdownBuyHold
Oct 16, 2026Goldman Sachsinit—Buy
Aug 6, 2026UBSmainBuyBuy
Aug 6, 2026KeybancmainOverweightOverweight
Jul 22, 2026Morgan StanleymainEqual-WeightEqual-Weight

About Elanco Animal Health Incorporated

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States
Website
elanco.com

News

Your note

Sign in to keep a note on ELAN — it syncs with the Stock Master app.

Insider holders

ELAN insider holders
InsiderRelationLatest transactionDateShares held
BETTINGTON TIMOTHY JOfficerSaleOct 14, 2026138,911
CABRAL RAMIRO MARTINOfficerStock Award(Grant)Feb 26, 2026290,366
DE BRABANDER ELLENOfficerStock Award(Grant)Mar 31, 2026280,821
HOOVER R DAVIDDirectorStock Award(Grant)May 20, 2026277,371
KINARD DAVID SOfficerStock Award(Grant)Feb 26, 2026217,697
KURZIUS LAWRENCE ERIKDirectorPurchaseAug 19, 2026188,647

Institution ownership

ELAN institution ownership
Holder% heldSharesValueReported
Dodge & Cox Inc.13.49%67,397,0251.62BJun 29, 2026
FMR, LLC11.40%56,948,8191.37BJun 29, 2026
Blackrock Inc.9.78%48,849,9731.18BJun 29, 2026
Primecap Management Company9.10%45,445,0121.09BJun 29, 2026
T. Rowe Price Investment Management, Inc.5.75%28,750,719692.46MJun 29, 2026
Dimensional Fund Advisors LP5.09%25,417,271612.17MJun 29, 2026

Fund ownership

ELAN fund ownership
Holder% heldSharesValueReported
Dodge & Cox Funds-Dodge & Cox Stock Fund8.63%43,107,5001.04BJun 29, 2026
iShares Trust-iShares Core S&P Mid-Cap ETF3.56%17,796,673428.63MSep 29, 2026
VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund3.55%17,751,139427.54MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.18%15,872,148382.28MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.29%11,448,318275.73MJun 29, 2026
Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total 2.07%10,339,390249.02MAug 30, 2026